VB6-845 is a humanized antibody fragment targeting EpCAM and fused with a deimmunized form of the cytotoxin Bouganin, developed for systemic use against metastatic cancer, showing effective pre-clinical cancer cell-killing properties. The DrugMonitor™ Anti-Citatuzumab Bogatox Antibody (VS-1224-YC283) is an anti-drug antibody (ADA) against Citatuzumab Bogatox. This drug-based antibody is raised in mice immunized with the Citatuzumab Bogatox. The anti-Citatuzumab Bogatox antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Citatuzumab Bogatox in samples.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Anti-Human EpCAM Recombinant Antibody Fab Fragment, 17-1A (Citatuzumab Bogatox)Recombinant antibody Fab to EpCAM. Citatuzumab bogatox (VB6-845) is a monoclonal antibody Fab fragment fused with bouganin, an ribosome inactivating protein from the plant Bougainvillea spectabilis. It has undergone pre-clinical trials for the treatment of ovarian cancer and other solid tumors.
There are currently no Customer reviews or questions for VS-1224-YC283. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.